stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Book value per share
Telix Pharmaceuticals Limited's book value per share at the end of fiscal 2025 was 1.2×, up 15.4% from 1.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 0.0×. Telix Pharmaceuticals Limited ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 1.2× | 15.38% |
| FY2024 | 1.1× | 243.71% |
| FY2023 | 0.3× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 2 more quarters | Free account |
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))